Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Kidney, liver & lung · 2025

Jascayd (nerandomilast)

The FDA approved Jascayd (nerandomilast) on October 7, 2025 to treat idiopathic pulmonary fibrosis.
Brand name
Jascayd
Generic name
nerandomilast
FDA approval date
October 7, 2025
Approved use (FDA wording)
To treat idiopathic pulmonary fibrosis
Company
Boehringer Ingelheim
Application
NDA218764
Dosage form / route
TABLET · ORAL
Boxed warning on label
Not listed
Category on this site
Kidney, liver & lung

Indications and usage, from the FDA label

JASCAYD is a phosphodiesterase 4 (PDE4) inhibitor indicated for: The treatment of idiopathic pulmonary fibrosis in adult patients. ( 1.1 ) The treatment of progressive pulmonary fibrosis in adult patients. ( 1.2 ) 1.1 Idiopathic Pulmonary Fibrosis JASCAYD is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients. 1.2 Progressive Pulmonary Fibrosis JASCAYD is indicated for the treatment of progressive pulmonary fibrosis (PPF) in adult patients.

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.